A step forward for LRRK2 inhibitors in Parkinson's disease.

Published in: Science translational medicine (2022)

A phase 1 clinical trial for kinase inhibitors targeting LRRK2 provides the foundation for testing the efficacy of LRRK2 kinase inhibitors in Parkinson's disease.

Keyphrases

clinical trial
randomized controlled trial
study protocol
drug delivery
phase ii
double blind